Physicochemical properties of peptides can provide key insights to potential success of oral delivery

BOONTON, N.J. , Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration."

The paper, authored by John Vrettos , PhD, Director of Formulation Development for Enteris BioPharma, and Kalpana Ramakrishnan , PhD, Manager of Business Development for Enteris BioPharma, explores the barriers to developing oral delivery of peptides and how pharmaceutical companies can overcome them. Oral administration of peptides offers several advantages while treating chronic conditions such as diabetes and obesity as they are less invasive and more cost effective compared to injections. The white paper is available to download via Drug Development & Delivery at https://drug-dev.com/whitepapers/whitepaper-key-considerations-in-oral-delivery-of-peptides-factors-to-consider-while-evaluating-oral-administration/.

"Molecule size, potency, and solubility are some of the key physicochemical properties that determine a peptide's suitability for oral delivery," Dr. Vrettos said. "The healthcare industry is in need of enabling drug delivery technologies with the capability to overcome barriers in oral delivery of peptides. Importantly, orally delivered medications may encourage patient compliance compared with more invasive approaches to administering drugs. Approximately 75% of peptides are delivered by injective routes, including subcutaneous injections which can be painful and difficult to incorporate into a daily routine."

Dr. Vrettos continued, "Enteris' Peptelligence® platform offers a 'triple-action' solution comprised of our enteric coating, protease inhibitor, and permeation enhancer.  When combined, these technologies have demonstrated an ability to improve the solubility and permeation of orally delivered peptides. These properties can potentially enable oral delivery of some peptide drugs for the first time, and we are excited to share our knowledge on oral delivery of peptides through this informative whitepaper."

Peptelligence is a novel formulation technology designed to enhance the oral delivery and bioavailability of selected drugs by enhancing the permeation of such compounds that are typically injected, including peptides and BCS class III and IV small molecules, and preventing their breakdown in the digestive tract.

Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services for innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence® and ProPerma®, and contract manufacturing (CMO) services using non-proprietary technologies. The company's proprietary technologies have been the subject of numerous feasibility studies and active development programs, some of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com.

View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-publishes-white-paper-examining-factors-to-consider-while-evaluating-oral-administration-of-peptides-301621732.html

Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer

Novavax Inc. said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer Inc. and German partner BioNTech SE and Moderna Inc. . The vaccine has now received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. It has also won authorization from the World Health Orga

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.

J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.

The latest clinical news from Bristol Myers Squibb (NYSE: BMY) was quite encouraging, sufficient to drive the pharmaceutical giant's stock higher on an otherwise uninspired day for the broader stock market. Bristol Myers Squibb's share price experienced a nearly 2% bump, a notably better showing than the S&P 500 index's more than 1% decline. Bristol Myers Squibb's good news from the lab was that its enduringly popular cancer drug Opdivo did quite well in its latest round of testing.

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Pharmaceutical giant Merck (NYSE: MRK) delivered outstanding second-quarter results in July, largely driven by its mainstay cancer blockbuster, Keytruda. The company reported 28% year-over-year total revenue growth and continues to develop Keytruda for new cancer indications. Under the radar, however, Keytruda returned some bad news in three separate late-stage clinical trials this summer.

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

Data shows that the Moderna bivalent vaccine can protect well against the original COVID-19 strain and the Omicron variant, said Health Minister Ong Ye Kung.

The New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said in a report that three of the top 10 selling drugs in the U.S. face no competition in the country and will cost Americans an estimated further $167 billion before they are expected to so. I-MAK said cheaper generic and biosimilar versions of Bristol-Myers Squibb and Pfizer's blood clot preventer Eliquis, AbbVie's Humira, and Amgen's Enbrel, both used to treat rheumatoid arthritis, will have been available in Europe for an average of 7.7 years before their expected U.S. launch. AbbVie, Amgen, Bristol-Myers Squibb, and Pfizer, did not immediately respond to requests for comment.

By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, provided an update in a letter to shareholders this week. With a broad pipeline of

Clinical trial results show that updated booster shots from Pfizer and Moderna are more effective.

AstraZeneca Plc (NASDAQ: AZN) said its Danicopan add-on anti-blood-clotting drug met a primary endpoint in the ALPHA phase 3 trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH). A prespecified interim analysis of the Phase 3 trial evaluating danicopan (ALXN2040) as an add-on to C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab) showed positive results. Related: AstraZeneca Settles Ultomiris-Related

The updated vaccines from Pfizer and Moderna are designed to specifically protect against the omicron variant.

Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete. On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published https://www.bmj.com/content/370/bmj.m3379 in the British Medical Journal. GSK and partner Vir Biotechnology's sotrovimab - which has generated billions in sales and became one of the British drugmaker's top sellers last year - was pulled off the U.S. market by the U.S. Food and Drug Administration (FDA) in April.

Right now, analysts up and down Wall Street are pounding the table on a little-known biotech company called MindMed (NASDAQ: MNMD). MindMed's lead candidate is MM-120, a proprietary formulation of lysergic acid diethylamide, better known as LSD. MindMed is developing MM-120 for the treatment of generalized anxiety disorder (GAD).

Pfizer Inc. on Thursday announced positive results from a late-stage trial of a meningococcal vaccine candidate called MenABCWY in adolescents and said it will submit an application for approval to the U.S. Food and Drug Administration in the fourth quarter. Meningococcal disease is a relatively rare but serious illness caused by a bacteria that can cause meningitis and can lead to death within 24 hours of infection. The current vaccination recommendations in the U.S. for adolescents and young a

Pharmaceutical companies can extend their drug patents, keeping generics off the market, in a process known as "evergreening." A report from the non-profit I-MAK details recent examples.

(Bloomberg) -- Stocks were mixed as investors weighed the prospect of large interest rate hikes by the Federal Reserve. Treasury yields and the dollar edged higher. Most Read from BloombergTerra Co-Founder Do Kwon Faces Arrest Warrant in South KoreaNY Judge Who Doesn’t Tolerate ‘Nonsense’ May Be Named Special Master in Trump CaseRay Dalio Does the Math: Rates at 4.5% Would Sink Stocks by 20%Stocks Rise as Dip Buyers Win Tug of War Over Fed: Markets WrapXi Unlikely to Throw Putin a Lifeline as Uk